OTC FILING WATCH · LIVEOfficial-source OTC filing intelligence
AUTOMATED SEC FILING DILIGENCE BRIEF
PUBLIC-RECORD DELIVERY

GUIDED THERAPEUTICS INC

CIK 0000924515Ticker GTHPSEC observed OTC

Automatically organized from the issuer’s official SEC submissions index. This brief is the starting evidence layer for buyer, FA, legal and broker-dealer review—not a legal conclusion or safety rating.

Open issuer dossier
Reporting & material events74

captured official filings

Registration & offering25

captured official filings

Ownership55

captured official filings

Governance6

captured official filings

WHAT THIS AUTOMATES

One evidence index instead of a manual filing hunt.

It groups recent reporting, registration/offer, ownership and governance filings, preserves the SEC source link and keeps a reusable chronology in the issuer’s record.

PROFESSIONAL DELIVERY LAYER

What teams can pay to automate next.

Cross-version text comparison, monitored alerts, change-specific diligence questions, CSV/PDF exports and a shared deal-team brief are the professional workflow built on this public evidence layer.

MACHINE-DETECTED FILING CHANGE RADAR

Public registration text delta

Comparing S-1 filed 2023-01-13 with S-1/A filed 2022-07-13.

Earlier SEC filingLatest SEC filing
362latest comparable sentences
109new-text candidates
79prior-text candidates not found

Tracked-term count changes

Counts are navigation signals, not conclusions. Open both official filings to determine materiality.

  • offering8 → 59+51
  • shares156 → 133-23
  • proceeds9 → 7-2
  • dilution0 → 1+1

Candidate disclosure excerpts

Only sentence-level additions or removals containing tracked diligence terms are shown. These are reading cues, not materiality findings.

New in latest filing
  • SUBJECT TO COMPLETION, DATED July 12, 2022 PRELIMINARY PROSPECTUS Up to 1,011,111 Shares of Common Stock and Up to 202,222 Pre-Funded Warrants to Purchase Shares of Common Stock and 2,022,222 Warrants to Purchase Shares of Common Stock Guided Therapeutics, Inc.
  • We are offering 1,011,111 shares of common stock pursuant to this prospectus at an assumed public offering price of $9.00 per share, together with 2,022,222 warrants (“Public Warrants”) to purchase shares of common stock.
  • The shares of common stock and Public Warrants will be separately issued, but the shares and warrants will be issued and sold to purchasers together.
Present in earlier filing, not found in latest
  • SUBJECT TO COMPLETION, DATED January 13, 2023 PRELIMINARY PROSPECTUS 61,397,663 Shares of Common Stock Guided Therapeutics, Inc.
  • However, we may receive proceeds in the aggregate amount of up to approximately $13,765,164 if all of the Private Warrants covered by this prospectus are exercised for cash (and, as applicable, not on a cashless basis), based on the initial per share exercise price of the Private Warrants.
  • This prospectus describes the general manner in which shares of common stock may be offered and sold by any selling stockholders.

Method: readable plain text is extracted from two official SEC HTML filings, then compared at sentence and tracked-term level. Formatting, exhibit differences and boilerplate may create false positives. This radar is not legal advice, a disclosure completeness opinion or a transaction recommendation.

DOWNLOAD EDITION

Save a project-ready issuer record.

US$29 one time. No subscription and no account. You receive the current printable Evidence Snapshot in this browser immediately after verified payment.

  • Source-linked filing chronology and registration path
  • Machine-detected amendment and tracked-term change view
  • Official-source index for project-file archiving and downloadable CSV export

Secure checkout by PayPal.

AUTOMATED EVIDENCE SNAPSHOT

Save this source-linked record

Download a printable HTML snapshot of the current public-record timeline and change view. A one-time download unlocks a saveable issuer record. Official sources remain controlling.

Unlock download · US$29
OFFICIAL SEC SUBMISSIONS

Captured filing chronology

Open Evidence Snapshot →
  1. 10-Q
    Reporting & material eventsOpen SEC filing →
  2. 4
    OwnershipOpen SEC filing →
  3. 4
    OwnershipOpen SEC filing →
  4. 4
    OwnershipOpen SEC filing →
  5. 4
    OwnershipOpen SEC filing →
  6. 10-K
    Reporting & material eventsOpen SEC filing →
  7. 4
    OwnershipOpen SEC filing →
  8. 8-K
    Reporting & material eventsOpen SEC filing →
  9. 4
    OwnershipOpen SEC filing →
  10. 10-Q
    Reporting & material eventsOpen SEC filing →
  11. 4
    OwnershipOpen SEC filing →
  12. 4
    OwnershipOpen SEC filing →
  13. 4
    OwnershipOpen SEC filing →
  14. 4
    OwnershipOpen SEC filing →
  15. 10-Q
    Reporting & material eventsOpen SEC filing →
  16. 4
    OwnershipOpen SEC filing →
  17. 4
    OwnershipOpen SEC filing →
  18. 4
    OwnershipOpen SEC filing →
  19. 10-Q
    Reporting & material eventsOpen SEC filing →
  20. 4
    OwnershipOpen SEC filing →
  21. 4
    OwnershipOpen SEC filing →
  22. 10-K
    Reporting & material eventsOpen SEC filing →
  23. 4
    OwnershipOpen SEC filing →
  24. 8-K
    Reporting & material eventsOpen SEC filing →
  25. 4
    OwnershipOpen SEC filing →
  26. 10-Q
    Reporting & material eventsOpen SEC filing →
  27. 4
    OwnershipOpen SEC filing →
  28. 4
    OwnershipOpen SEC filing →
  29. 4
    OwnershipOpen SEC filing →
  30. 8-K
    Reporting & material eventsOpen SEC filing →
  31. 4
    OwnershipOpen SEC filing →
  32. 4
    OwnershipOpen SEC filing →
  33. 4
    OwnershipOpen SEC filing →
  34. 4
    OwnershipOpen SEC filing →
  35. 4
    OwnershipOpen SEC filing →
  36. 4
    OwnershipOpen SEC filing →
  37. 4
    OwnershipOpen SEC filing →
  38. 10-Q
    Reporting & material eventsOpen SEC filing →
  39. 4
    OwnershipOpen SEC filing →
  40. 10-Q
    Reporting & material eventsOpen SEC filing →
  41. 4
    OwnershipOpen SEC filing →
  42. 4
    OwnershipOpen SEC filing →
  43. 10-K
    Reporting & material eventsOpen SEC filing →
  44. 4
    OwnershipOpen SEC filing →
  45. 4
    OwnershipOpen SEC filing →
  46. SC 13G/A
    OwnershipOpen SEC filing →
  47. SC 13G/A
    OwnershipOpen SEC filing →
  48. 4
    OwnershipOpen SEC filing →
  49. 10-Q
    Reporting & material eventsOpen SEC filing →
  50. 4
    OwnershipOpen SEC filing →
  51. 4
    OwnershipOpen SEC filing →
  52. 4
    OwnershipOpen SEC filing →
  53. 10-Q
    Reporting & material eventsOpen SEC filing →
  54. 4
    OwnershipOpen SEC filing →
  55. 4
    OwnershipOpen SEC filing →
  56. 4
    OwnershipOpen SEC filing →
  57. 4
    OwnershipOpen SEC filing →
  58. 4
    OwnershipOpen SEC filing →
  59. 4
    OwnershipOpen SEC filing →
  60. 4
    OwnershipOpen SEC filing →
Evidence boundary

Only official SEC submission-index facts are automated here. The brief does not determine shell status, beneficial ownership, capitalization, legal compliance, valuation, active-trading status or transaction suitability. Those questions require the appropriate source documents and independently retained professionals.